Does Wegovy Delay Gastric Emptying — and Does It Matter?

What the trial data actually show about semaglutide and stomach motility

The link between GLP-1 receptor agonists and delayed gastric emptying has been documented in clinical pharmacology studies for over a decade. For semaglutide specifically, a dedicated gastric-emptying sub-study published in the context of the wider STEP programme found that the medicine significantly slowed the rate of gastric emptying at four weeks into treatment. Crucially, by twelve weeks this effect had attenuated substantially, even though weight loss continued to progress. This finding matters because it suggests the medicine's long-term efficacy relies more on central appetite suppression and hormonal signalling than on keeping food in the stomach indefinitely. The detailed breakdown of the gastric-emptying evidence for Wegovy covers these study timelines in full. The NHS notes that semaglutide works partly by slowing digestion, which prolongs the sensation of fullness after eating. That early-weeks window, when emptying is most slowed, is also when nausea tends to peak — the two effects share the same root.

For weight-loss outcomes overall, the STEP 1 trial (68 weeks, 2.4 mg semaglutide versus placebo, published in the New England Journal of Medicine) reported an average body-weight reduction of roughly 15%. Gastric slowing is one piece of a multi-pathway picture.

Why the timing of gastric slowing explains so many early side effects

Most of the gastrointestinal side effects people report in their first few pens (nausea, a feeling of fullness after small amounts of food, occasional vomiting, reflux) map directly onto what happens when stomach emptying is delayed. Food sits longer. Acid has more time to irritate the stomach lining. Signals of fullness fire earlier than they used to. This is not a sign something is going wrong; it is the medicine behaving as intended, at a dose (0.25 mg starting) specifically chosen to let the body adjust before the therapeutic doses begin.

For most people, these effects ease noticeably over two to four weeks as the gut adapts. Eating smaller portions, chewing thoroughly, and avoiding fatty or highly processed meals during the early escalation period can help considerably. If symptoms are severe or persistent, that is a conversation for a prescriber, not something to push through alone. Our page on Wegovy and gastritis addresses the question of whether ongoing stomach irritation warrants further investigation. The NHS medicines page for semaglutide lists the full side-effect profile and the signs that need prompt medical attention.

The practical knock-on: oral medicines, timing and what to tell your prescriber

Slowed gastric emptying does not only affect food, it changes how quickly other orally-taken medicines reach the small intestine for absorption. In practice this is most relevant for medicines with a narrow therapeutic window, time-sensitive drugs such as levothyroxine, and oral contraceptives. The NHS guidance on weight-management injections specifically notes that women on the contraceptive pill should discuss their options with a clinician before starting semaglutide, though the current evidence base suggests a smaller interaction risk here than with tirzepatide. Our page on Wegovy and menstrual changes covers the contraception question in more detail.

The practical rule is straightforward: tell every clinician involved in your care, including your GP and any hospital specialist, that you are taking Wegovy. This applies particularly ahead of any surgical or endoscopic procedure, since a fuller stomach carries anaesthetic risk. The wider look at delays associated with Wegovy explores procedural timing in more depth. Spacing oral medicines from your injection by a consistent window, or switching to non-oral formulations where that is an option, is worth raising at your next clinical review rather than managing silently.

What this means if you are weighing up treatment

Understanding the gastric-emptying mechanism helps set realistic expectations. The nausea that catches some people off guard in week two is the same process that is making them feel full on a smaller lunch. One thing our prescribers hear fairly regularly is that people wish they had known this before starting, it reframes an uncomfortable side effect as evidence the medicine is working, rather than a reason to stop. Gastric slowing also means Wegovy is not suited to everyone. Active gastroparesis (delayed gastric emptying as a pre-existing condition) is a reason to approach GLP-1 medicines with particular caution and discuss with a specialist. See our resource on Wegovy in the context of pre-existing delayed gastric emptying if that applies to you.

Wegovy is a prescription-only medicine. A prescriber reviews your full medical history, including any existing GI conditions or medications that could interact, before recommending it. If you want to explore whether treatment is appropriate for your circumstances, speak to our prescribers through a free consultation, the same day your answers are submitted, a GPhC-registered clinician reviews them. And if you are thinking about the broader cost picture, our guide to accessing Wegovy in the UK covers what private prescriptions typically involve.